Literature DB >> 20510522

Population pharmacokinetics of a propofol bolus administered in patients with major burns.

Susumu Yamashita1, Kotaro Kaneda, Tae-Hyung Han.   

Abstract

OBJECTIVE: In operating theaters and burn units, propofol is commonly used for sedation and anesthesia in patients with major burns. This study determined the population pharmacokinetics of propofol in burns and identified clinically significant covariates.
METHOD: Seventeen adults, age 42±10 (mean±SD) years, with 41±19% total body surface area burns, were enrolled at 16±14 days after-burn. Non-burn adults (n=19) served as controls. After an intravenous bolus of 2mg/kg propofol, the plasma concentration was determined at designated times for up to 4.5h. Concentration-time profiles were analyzed using nonlinear mixed-effect modeling.
RESULTS: A three-compartment model gave the best fit. The volume of distribution of the central compartment (V(1)) was considerably greater in the burned than non-burned group (48.4 L vs. 27.6 L, respectively). The clearances of the central (CL(1)) and slow peripheral (CL(3)) compartments were higher in burn patients (4.2 L/min vs. 1.7 L/min and 3.6 L/min vs. 1.1 L/min, respectively). Adding the covariates BURN to V(1), CL(1), and CL(3) and WT (weight) to CL(1) significantly improved the model performance.
CONCLUSION: The pharmacokinetic characteristics of a propofol bolus administered in patients with major burns were enhanced clearance and expanded volume of distribution. BURN and WT were the important covariates. For sedation or anesthesia induction, a higher than recommended dose of propofol may be required to maintain therapeutic plasma drug concentrations in patients with severe burns. Vigilance regarding the burned individual and careful titration of hypnotics to the desired effect cannot be overemphasized.
Copyright © 2010 Elsevier Ltd and ISBI. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20510522     DOI: 10.1016/j.burns.2010.03.003

Source DB:  PubMed          Journal:  Burns        ISSN: 0305-4179            Impact factor:   2.744


  4 in total

1.  High-performance liquid chromatographic determination of propofol in human plasma: comparison of different heteroscedastic calibration curve models.

Authors:  Pooria Taghavi Moghaddam; Mohammad Reza Pipelzadeh; Sholeh Nesioonpour; Nader Saki; Saeed Rezaee
Journal:  Adv Pharm Bull       Date:  2014-08-10

2.  Pharmacokinetic evaluation and in vitro-in vivo correlation (IVIVC) of novel methylene-substituted 3,3' diindolylmethane (DIM).

Authors:  Apurva R Patel; Shawn D Spencer; Mahavir B Chougule; Stephen Safe; Mandip Singh
Journal:  Eur J Pharm Sci       Date:  2012-02-08       Impact factor: 4.384

3.  Comparison of the pharmacokinetics of linezolid in burn and non-burn rabbits.

Authors:  Jian-Li Ma; Lei Gao; Xiang Li; Wan-Li Chu; Yong-Qiang Feng; Xiao-Qin Wang; Qing-Zhe Zhang
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2014-06-13       Impact factor: 2.441

4.  [Influence of propofol dose and blood components on duration of electrical seizures in electroconvulsive therapy].

Authors:  María Luisa González Moral; Carmen Selva Sevilla; Patricia Romero Rodenas; María Teresa Tolosa Pérez; Marta Lucas Pérez-Romero; Mar Domato Lluch; Manuel Gerónimo Pardo
Journal:  Braz J Anesthesiol       Date:  2018-08-22
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.